| SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma E Andreano, G Piccini, D Licastro, L Casalino, NV Johnson, I Paciello, ... Proceedings of the National Academy of Sciences 118 (36), e2103154118, 2021 | 480* | 2021 |
| Extremely potent human monoclonal antibodies from COVID-19 convalescent patients E Andreano, E Nicastri, I Paciello, P Pileri, N Manganaro, G Piccini, ... Cell 184 (7), 1821-1835. e16, 2021 | 218 | 2021 |
| Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants E Andreano, I Paciello, G Piccini, N Manganaro, P Pileri, I Hyseni, ... Nature 600 (7889), 530-535, 2021 | 150 | 2021 |
| Immune response in COVID-19: what is next? Q Li, Y Wang, Q Sun, J Knopf, M Herrmann, L Lin, J Jiang, C Shao, P Li, ... Cell Death & Differentiation 29 (6), 1107-1122, 2022 | 136 | 2022 |
| Lymphocyte communication in myocardial ischemia/reperfusion injury SE Boag, E Andreano, I Spyridopoulos Antioxidants & redox signaling 26 (12), 660-675, 2017 | 72 | 2017 |
| SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies E Andreano, R Rappuoli Nature medicine 27 (5), 759-761, 2021 | 71 | 2021 |
| Vaccine evolution and its application to fight modern threats E Andreano, U D'Oro, R Rappuoli, O Finco Frontiers in immunology 10, 1722, 2019 | 46 | 2019 |
| SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv 2020 E Andreano, G Piccini, D Licastro, L Casalino, NV Johnson, I Paciello, ... Google Scholar, 2020 | 38 | 2020 |
| Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody JL Torres, G Ozorowski, E Andreano, H Liu, J Copps, G Piccini, L Donnici, ... Proceedings of the National Academy of Sciences 119 (20), e2120976119, 2022 | 31 | 2022 |
| Immunodominant antibody germlines in COVID-19 E Andreano, R Rappuoli Journal of Experimental Medicine 218 (5), 2021 | 30 | 2021 |
| B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response E Andreano, I Paciello, G Pierleoni, G Piccini, V Abbiento, G Antonelli, ... Nature Communications 14 (1), 53, 2023 | 28* | 2023 |
| Anatomy of Omicron BA. 1 and BA. 2 neutralizing antibodies in COVID-19 mRNA vaccinees E Andreano, I Paciello, S Marchese, L Donnici, G Pierleoni, G Piccini, ... Nature communications 13 (1), 3375, 2022 | 25 | 2022 |
| Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients E Andreano, E Nicastri, I Paciello, P Pileri, N Manganaro, G Piccini, ... bioRxiv, 2020 | 24 | 2020 |
| Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection S Lanini, S Milleri, E Andreano, S Nosari, I Paciello, G Piccini, A Gentili, ... Nature Communications 13 (1), 2263, 2022 | 17* | 2022 |
| The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors E Andreano, I Paciello, M Bardelli, S Tavarini, C Sammicheli, ... EMBO Molecular Medicine 13 (6), e14035, 2021 | 16 | 2021 |
| Human monoclonal antibodies for discovery, therapy, and vaccine acceleration E Andreano, A Seubert, R Rappuoli Current opinion in immunology 59, 130-134, 2019 | 16 | 2019 |
| Vaccines as remedy for antimicrobial resistance and emerging infections M Troisi, E Andreano, C Sala, A Kabanova, R Rappuoli Current Opinion in Immunology 65, 102-106, 2020 | 15 | 2020 |
| Emerging roles of SARS-CoV-2 Spike-ACE2 in immune evasion and pathogenesis CT Baldari, A Onnis, E Andreano, G Del Giudice, R Rappuoli Trends in Immunology 44 (6), 424-434, 2023 | 14 | 2023 |
| Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations CM Trombetta, G Piccini, G Pierleoni, M Leonardi, F Dapporto, S Marchi, ... Communications biology 5 (1), 903, 2022 | 14 | 2022 |
| mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA. 4 and BA. 5 E Andreano, I Paciello, G Pierleoni, G Maccari, G Antonelli, V Abbiento, ... Nature Communications 14 (1), 1734, 2023 | 13 | 2023 |
